Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oneness Biotech CoROCO:4743 -3.38%59 Days Payable is 9.36 as of Dec. 2025, which is 32% below its 10-year median of 13.85. GuruFocus rates ROCO:4743 with a GF Score™ of 59/100 and a GF Value™ of NT$81.63 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, Oneness Biotech Co ranks worse than 97.43% on this metric.
The historical rank and industry rank for Oneness Biotech Co's Days Payable or its related term are showing as below:
ROCO:4743'
s Days Payable Range Over the Past 10 Years
Min: 2.6 Med: 13.85 Max: 816.89
Current: 8.37
During the past 13 years, Oneness Biotech Co's highest Days Payable was 816.89. The lowest was 2.60. And the median was 13.85.
ROCO:4743's Days Payable is ranked worse than 97.43% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:4743: 8.37
Oneness Biotech Co's Days Payable
declined
from Dec. 2024 (10.05) to Dec. 2025 (9.36).
It may suggest that Oneness Biotech Coaccelerated paying its suppliers.
Oneness Biotech Co Days Payable Related Terms
Oneness Biotech Co Days Payable Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4743 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Oneness Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Oneness Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oneness Biotech Co (ROCO:4743) has a Days Payable of 9.36 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oneness Biotech Co and its competitors. This is 32% below median its historical median of 13.85. Over the past decade, Oneness Biotech Co's Days Payable has ranged from 2.60 to 816.89. According to the industry distribution chart, Oneness Biotech Co ranks #683 out of 701 companies in the Biotechnology industry, placing it in the top 97.4%.
Is Oneness Biotech Co's Days Payable too high?
Oneness Biotech Co's current Days Payable of 9.36 is 32% below median its 10-year median of 13.85. Over the past 10 years, this metric has ranged from a low of 2.60 to a high of 816.89. The Biotechnology industry median Days Payable is 112.84. Oneness Biotech Co's value of 9.36 is 91.7% below this industry median. Based on the distribution chart, Oneness Biotech Co ranks #683 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oneness Biotech Co has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #683 out of 701 companies for Days Payable. This places Oneness Biotech Co in the lower half of its industry. The industry median Days Payable is 112.84. Oneness Biotech Co's value of 9.36 is 91.7% below this benchmark. Historically, Oneness Biotech Co's own Days Payable has ranged from 2.60 to 816.89 over the past decade. While the company's 10-year median is 13.85 vs. the industry median of 112.84, Oneness Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current Days Payable of 9.36 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oneness Biotech Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current Days Payable is 9.36, which is 32% below median its own 10-year median of 13.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Oneness Biotech Co (ROCO:4743) is currently considered Possible Value Trap. The stock's GF Value™ is NT$81.63, compared to a current price of NT$48.60 — trading 40.5% below its estimated fair value. The current Days Payable is 9.36, which is 32% below median its 10-year median of 13.85 and 91.7% below the Biotechnology industry median of 112.84. Oneness Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Oneness Biotech Co (ROCO:4743), the current Days Payable is 9.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (ROCO:4743) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of NT$48.60 is trading 40.5% below its estimated GF Value™ of NT$81.63.
GuruFocus considers Oneness Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4743:
Days Payable: 9.36 (32% below median its 10-year median of 13.85)
GF Value™: NT$81.63 vs. price of NT$48.60 (40.5% below fair value)
Industry Position: 91.7% below the Biotechnology median (#683 of 701)
No single metric tells the full story. See the ROCO:4743 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score
Get the complete analysis for ROCO:4743
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4743 has been successfully added to your 
